JCR.F JCR Pharmaceuticals Co., Ltd.
- Market cap
- EUR 334M
- P/E
- -
- P/B
- 1.48x
- ROE
- -17.7%
- Dividend yield
- 4.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is JCR.F undervalued?
Graham numberThe Graham number of JCR Pharmaceuticals Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
JCR Pharmaceuticals Co., Ltd. fundamental analysis
No fundamental analysis for JCR Pharmaceuticals Co., Ltd. yet.
JCR Pharmaceuticals Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusi…
Full company profileJCR Pharmaceuticals Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
JCR Pharmaceuticals Co., Ltd. annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 51.1B | 34.3B | 42.9B | 33.1B | 40.3B | 38.8B |
| Gross Profit | 40.6B | 25.5B | 31.3B | 22.2B | 30.2B | 29.8B |
| Operating Income | 19.9B | 4.98B | 7.53B | -6.22B | 556M | -8.42B |
| EBITDA | - | 7.45B | 10.5B | -2.45B | 6.18B | -7.71B |
| Net Income | 14.5B | 3.77B | 5.51B | -4.46B | 2.18B | -7.63B |
| EPS | 117 | 30 | 44 | -37 | 18 | -63 |
| Balance Sheet | ||||||
| Total Assets | 97.1B | 94.9B | 102B | 105B | 109B | 106B |
| Total Liabilities | 46.0B | 42.5B | 45.8B | 57.4B | 61.9B | 62.8B |
| Shareholders' Equity | 50.9B | 52.2B | 56.2B | 47.0B | 46.9B | 43.2B |
| Cash & Short-term Investments | 30.7B | 13.3B | 18.8B | 13.2B | 14.0B | 9.66B |
| Cash Flow | ||||||
| Operating Cash Flow | 9.29B | -5.50B | 9.31B | -5.49B | -135M | - |
| Capital Expenditure | 11.4B | 8.56B | 1.53B | 9.89B | 11.6B | 0.00 |
| Free Cash Flow | -2.12B | -14.1B | 7.79B | -15.4B | -11.7B | - |
| Ratios | ||||||
| ROE | 28.5% | 7.2% | 9.8% | -9.5% | 4.6% | -17.7% |
| ROA | 14.9% | 4.0% | 5.4% | -4.3% | 2.0% | -7.2% |
| Net Profit Margin | 28.4% | 11.0% | 12.8% | -13.5% | 5.4% | -19.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
JCR Pharmaceuticals Co., Ltd. dividends
- Dividend yield
- 4.03%
- Forward dividend
- 0.11 EUR
- Payout ratio
- -
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | JPY 2.51B | 21 | - |
| 2024 | JPY 2.50B | 20 | 45.4% |
| 2023 | JPY 2.74B | 22 | 72.6% |
| 2022 | JPY 2.17B | 18 | 15.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns JCR Pharmaceuticals Co., Ltd.
- Insiders 36.97%
- Institutions 13.94%
- Public & others 49.08%
- Shares outstanding 122M
- Free float 73.9M
JCR Pharmaceuticals Co., Ltd. company profile
- Company name
- JCR Pharmaceuticals Co., Ltd.
- Ticker
- JCR.F
- ISIN
- JP3701000006
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 985
- Fiscal year end
- March
- Address
- 3-19 Kasuga-cho, Ashiya, Japan, 659-0021
- Phone
- 81 7 9732 1995
- Website
- jcrpharm.co.jp
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was founded in 1975 and is based in Ashiya, Japan.
JCR Pharmaceuticals Co., Ltd. management
10- Andrea Spezzi FFPM, M.D.Senior Managing Executive Officer of Development Division & Director · born 1965
- Mr. Hiroyuki Sonoda Ph.D.President, Chief Scientific Officer & Representative Director · born 1978
- Mr. Shin AshidaFounder & Director · born 1943
- Yoshihiro OtaDirector of Accounting Department & Corporate Strategy Department (Finance)
- Mr. Yutaka HondaSenior Managing Executive Officer, Exec Director of Administration Div. & Head of Exec Office
- Mr. Hiroyuki FukuyaExec Off, Dir of Legal & Compliance, Internal Control Dept and Chief Legal & Compliance Off
- Takafumi ShimizuDirector of Marketing Dept. & Sales Division
- Tomohiko MiyagawaExecutive Officer and Executive Director of Sales Division
- Shinji OkamotoDirector of Human Resources Department & Administration Division
- Katsuya NishinoExecutive Vice President · born 1956